Biotica has developed BPRxTM Technology, which is a novel combinatorial library of phytocannabinoids and endocannabinoids for treating various diseases.
The endocannabinoid system (ECS) is composed of two G protein-coupled receptors (GPCRs), the cannabinoid CB1 and CB2 receptors, and the two main endogenous lipid ligands of such receptors, anandamide and 2-arachidonoyl-glycerol (2-AG). The ECS is a pleiotropic signalling system involved in all aspects of mammalian physiology and pathology, and for this reason it represents a potential target for the design and development of new therapeutic drugs. Over the past decades, the endocannabinoid system has been widely studied, owing to its broad range of physiological effects. ECS system encompasses a wide range of lipid mediators, proteins and receptors, which together can be considered as the ‘endocannabinoidome’
Biotica has created an extensive library of various phytocannabinoid and endocannabinoid combinations in effective dose concentrations called BPRxTM to modulate specific signalling to treat different human diseases.
BPRxTM-060216: Lead drug candidate to treat Eosinopilic Esophagitis (EoE)
Eosinophilic Esophagitis (EoE) also known as “asthma of the esophagus” is a chronic immune mediated disorder of the esophagus affecting both children and adults. EoE is a major cause of chronic esophagitis, second to gastro-esophageal reflux. Patients are diagnosed with abdominal pain, vomiting, and dysphagia, difficulty swallowing and food impaction. It can be refractory to standard treatment with strict dietary food allergen avoidance, off-label use of swallowed topical steroids and proton pump inhibitors.
- EoE is a orphan disease.
- Overall prevalence is 57 per 100,000 United States children and adults up to age 64 .
- EoE profoundly impacts quality of life in EoE patients.
- This life-long disease of adults and children has a United States prevalence of approximately 181,000.
- An economic burden of $1.4B in annual direct health care.
- There are no FDA-approved EoE treatments.
BPRxTM-060216 is our lead drug formulation for treating EoE. We have completed proof of concept studies and currently conducting preclinical studies
BPRxTM–060234: Lead drug candidate to treat early stages of Alzheimer’s disease
Alzheimer’s disease (AD) represents a complex class of debilitating brain diseases that mostly affects people aged 65 and older. AD is characterized by progressive loss of neurons in the hippocampus and cortex, which results in the shrinkage of brain. Basically, the brain cells required to process, store and retrieve information are killed, which is characteristic of a neurodegenerative process.
AD is a progressive neurodegenerative disorder, which killed half a million people in 2010. It is the sixth leading cause of death in US. It is estimated that by 2050, the number of people with AD may nearly triple, from 5 million to as many as 16 million, barring the development of medical breakthroughs to prevent, slow or stop the disease. Existing medications, which mostly treat symptoms, have combined sales of about $3 billion today. Any drug, which cure or manage to slow the progression of AD will be about $5-6 billion dollar market.
Biotica have identified a combination of two patent-pending drug actives – BPRx060234- which simultaneously targets both amyloid plaques and tau phosphorylation, the two major causative agents of AD.
Biotica has applied for two world-wide patent rights for the platform technologies and for specific novel drug formulations. We are actively procuring a portfolio of patents, trademarks, and trade secrets to reinforce and protect our technologies. We are conducting discovery research both in-house and with joint development agreements using our platform technology. Further, we are currently exploring technology licensing from major academic institutions to complement our tech-portfolio.